TherapeuticsMD
TXMD
43 hedge funds and large institutions have $19.4M invested in TherapeuticsMD in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 9 closing their positions.
41% more capital invested
Capital invested by funds: $13.8M → $19.4M (+$5.67M)
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
14.73% more ownership
Funds ownership: 21.98% → 36.71% (+15%)
0% more funds holding
Funds holding: 43 → 43 (0)
44% less call options, than puts
Call options by funds: $1.6M | Put options by funds: $2.86M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.53M |
| 2 |
CC
Clearline Capital
New York
|
+$1.38M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$735K |
| 4 |
BlackRock
New York
|
+$679K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$394K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$409K |
| 2 |
Millennium Management
New York
|
-$408K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
-$113K |
| 4 |
AMG
Asset Management Group
Stamford,
Connecticut
|
-$98K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$72.1K |
TXMD Hedge Fund Activity: Q4 2022 in Review
43 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q4 2022, worth a combined $19.4M — up 41% from $13.8M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TXMD positions and 9 closed out — a net gain of 2 holders — while 11 added to existing stakes and 8 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $3.53M. The largest seller was J. Goldman & Co, cutting an estimated $409K.
- 43 institutional investors held TherapeuticsMD (TXMD) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $19.4M of TherapeuticsMD stock for Q4 2022, up 41% quarter-over-quarter.
- 11 funds opened new TherapeuticsMD positions in Q4 2022 and 9 closed out, a net change of +2 holders.
- The largest TherapeuticsMD buyer in Q4 2022 was Rubric Capital Management (New York), an estimated $3.53M added.
- The largest TherapeuticsMD seller in Q4 2022 was J. Goldman & Co, an estimated $409K sold.
Based on aggregated 13F filings for Q4 2022.